Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
argenx
200 participants
Aug 11, 2025
OBSERVATIONAL
Conditions
Summary
The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod. As this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to the standard of care. Each participant will be prospectively followed for up to 2 years from the date of initial administration of efgartigimod.
Eligibility
Inclusion Criteria4
- Aged ≥18 years at time of providing informed consent
- Diagnosed with CIDP
- Planned to be receiving efgartigimod treatment within the CIDP treatment label of efgartigimod in the participant's respective country
- Efgartigimod treatment-naïve at time of screening
Exclusion Criteria2
- Polyradiculoneuropathy due to any other cause(s)
- Current participation in any interventional clinical study at time of screening, or planned participation before initiation of efgartigimod
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Efgartigimod treatment per country-specific label for the treatment of CIDP
Locations(19)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07264426